Get the Stockscreener App
0.85
6.50%
0.0533
Xilio Therapeutics Inc stock is traded at $0.85, with a volume of 1.03M.
It is up +6.50% in the last 24 hours and up +3.72% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
See More
Previous Close:
$0.7967
Open:
$0.8
24h Volume:
1.03M
Relative Volume:
1.63
Market Cap:
$44.36M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2872
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
+2.16%
1M Performance:
+3.72%
6M Performance:
+13.10%
1Y Performance:
-35.72%
1-Day Range:
$0.80
$0.8592
1-Week Range:
$0.7714
$0.8989
52-Week Range:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.856 | 41.29M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
How Xilio Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Setups & Free Accurate Trade Setup Notifications - newser.com
Why Xilio Therapeutics Inc. stock is in analyst buy zone2025 Growth vs Value & Free Community Supported Trade Ideas - newser.com
Is it too late to sell Xilio Therapeutics Inc.Earnings Overview Summary & Weekly High Return Opportunities - newser.com
Xilio Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Tick level data insight on Xilio Therapeutics Inc. volatilityEarnings Miss & Community Verified Trade Signals - newser.com
Building trade automation scripts for Xilio Therapeutics Inc.July 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
Using data models to predict Xilio Therapeutics Inc. stock movementJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
What Fibonacci levels say about Xilio Therapeutics Inc. reboundMarket Growth Report & Weekly Top Gainers Trade List - newser.com
Why analysts remain bullish on Xilio Therapeutics Inc. stockJuly 2025 Momentum & AI Enhanced Execution Alerts - newser.com
Tools to assess Xilio Therapeutics Inc.’s risk profileJuly 2025 Trends & Risk Managed Investment Signals - newser.com
What makes Xilio Therapeutics Inc. stock attractive to growth fundsJuly 2025 Intraday Action & Daily Stock Trend Reports - newser.com
Can Xilio Therapeutics Inc. stock deliver sustainable ROEPortfolio Gains Report & Stock Timing and Entry Methods - newser.com
Will Xilio Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
Is Xilio Therapeutics Inc. stock a buy before product launchesJuly 2025 Reactions & Verified Stock Trade Ideas - newser.com
Is Xilio Therapeutics Inc a good long term investmentLong-Term Growth Stocks & Small Entry Cost Investments - earlytimes.in
Why Xilio Therapeutics Inc. stock remains on watchlists2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - newser.com
Best data tools to analyze Xilio Therapeutics Inc. stockMarket Trend Review & AI Driven Stock Reports - newser.com
What machine learning models say about Xilio Therapeutics Inc.July 2025 Update & Safe Entry Zone Identification - newser.com
Volume spikes in Xilio Therapeutics Inc. stock – what they meanPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
How Xilio Therapeutics Inc. stock compares to market leadersWeekly Earnings Recap & Real-Time Stock Price Movement Reports - newser.com
How geopolitical tensions affect Xilio Therapeutics Inc. stockProfit Target & Weekly Market Pulse Alerts - newser.com
Xilio to present vilastobart phase 2 data at SITC annual meeting - Investing.com Australia
What the charts say about Xilio Therapeutics Inc. todaySwing Trade & Technical Pattern Based Buy Signals - newser.com
Volatility clustering patterns for Xilio Therapeutics Inc.July 2025 Catalysts & Smart Investment Allocation Insights - newser.com
Is Xilio Therapeutics Inc. stock safe for conservative investorsWeekly Profit Recap & Verified Momentum Stock Watchlist - newser.com
Xilio to present vilastobart phase 2 data at SITC annual meeting By Investing.com - Investing.com South Africa
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):